<DOC>
	<DOCNO>NCT00268671</DOCNO>
	<brief_summary>Study Objectives : - To determine MTD ( maximal tolerate dose ) recommend dose weekly docetaxel cisplatin combination regimen locoregional recurrent/metastatic Squamous Cell Carcinoma Head Neck ( SCCHN ) - To determine response rate recommend dose - To determine safety tolerability recommend dose</brief_summary>
	<brief_title>Docetaxel Squamous Cell Carcinoma Head Neck ( TAX + Cisplatin SCCHN )</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma , Squamous Cell</mesh_term>
	<mesh_term>Head Neck Neoplasms</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<criteria>Histologically confirm ( original primary tumor ) locoregional recurrent and/or metastatic follow prior radiotherapy and/or surgery amenable curative local therapy SCCHN Measurable disease define least long diameter measure 20 mm conventional CT 10 mm spiral CT . Physical measurement allow long diameter 20 mm caliper measurement . ECOG performance status 02 Adequate bone marrow hepatic function evidence follow : Hematology ( Bone marrow ) : Neutrophils ≥ 1.50 x 10^9/L Platelets ≥ 100 x 10^9/L Hemoglobin ≥ 10 g/dL Hepatic function : AST and/or ALT : &lt; 2X ULN ( Upper Limit Normal ) Bilirubin &lt; 1X ULN Adequate renal function calculate measured glomerular filtration rate &gt; 60 ml/min calculate Cockcroft Gault method No severe intercurrent illness serious illness medical condition include limited : Unstable cardiac disease despite treatment , myocardial infarction within 6 month prior study entry . Active uncontrolled infection Active peptic ulcer Chronic obstructive pulmonary disease require hospitalization year precede study entry No prior chemotherapy recurrent/advanced SCCHN platinum taxane regimen ( primary radiosensitizing platinum allow ) . No diagnosed malignancy basal cell carcinoma skin cervix carcinoma situ Prior therapy taxanes either adjuvant , neoadjuvant , concurrent advanced stage disease Prior chemotherapy locoregional recurrent/metastatic SCCHN palliative intent Contraindications medical history ( i.e . know hepatitis , HIV ) physical exam laboratory test ( hematology , biochemistry ) 12lead electrocardiogram blood pressure pulse Pregnancy Breastfeeding Treatment investigational product last 4 week study entry Likelihood require treatment study period drug permit clinical study protocol Presence sequelae gastrointestinal , liver kidney disease , condition know interfere absorption , distribution , metabolism , excretion drug History hypersensitivity study drug ( ) drug similar chemical structure Impaired hepatic function , show bilirubin great upper limit normal and/or AST great 2 time upper limit normal Impaired renal function , show measure calculated creatinine clearance &lt; 60 ml/min absolute creatinine level &gt; 1.5 upper limit normal</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>December 2009</verification_date>
</DOC>